Marc
Do you think this is GLGS?
agora-inc.com
The Secret Technology That Will Change The World
By George Rayburn
"This opportunity simply dwarfs what our
research normally turns up."
-- David Lashmet
You don't get many opportunities to make $250,000, quickly...
Especially with an initial investment of only $2,500...
Pirate biotech analyst Dave Lashmet found a tiny company (it has fewer than 20 employees) in Boston several years ago. He's been watching the company closely since. It's been developing a new, secret technology - one that was recently included in MIT's "10 emerging technologies that will change the world" list.
"These are not the latest crop of gadgets and gizmos," wrote MIT's Technology Review, "they are completely new technologies that could soon transform computing, medicine, manufacturing, transportation, and our energy infrastructure."
The technology I'm going to tell you about has also been written up in The Wall Street Journal, The Boston Business Journal, The Boston Globe, and more than a half-dozen scientific publications, including one journal called Research and Development Directions, earlier this year.
John Axford, a member of England's Royal Society, calls this technology "one of the last frontiers."
It will be put to use in a $60 billion industry. And few people outside the company know how far along they are to commercial success. David Lashmet is one of them...
Meanwhile, much of our economy is slowing... even shrinking... but this industry is growing incredibly fast. According to Fortune magazine, the number of people who will be affected by this versatile technology will soon double.
Right now though, the company behind this technology is tiny.
It is valued in the stock market for under $50 million. Its CEO makes only $230,000 a year -- a far cry from the average corporate CEO salary of $7.4 million, according to a recent survey in Business Week.
Best of all, you can buy this small company for less than $1.25 a share. You can control 500 shares for about $500.
This stock has gone up more than 100% in the past year -- and based on what we've learned -- in the next 12 months, it has a long, long way to go. We think $10 per share is a reasonable 12-month target.
There's a stunning amount of money to be made here.
TURN A FEW HUNDRED DOLLARS INTO $250,000
If you are looking for an opportunity to turn a few hundred dollars into a small fortune, this could be it.
As I mentioned, this company has a market cap of less than $50 million (that's all the shares outstanding multiplied by the stock price). As a point of reference, IBM has a market cap of about $155 BILLION. So the company I'm talking about is about 1/3000th the size of IBM.
This company is so small, in fact, that we can't even consider writing about it in one of our more broadly circulating newsletters. If we did -- or if I give away too much away about it here -- people would figure out what it is. And the share price would go through the roof. Keep in mind that, on any given day, only around 1 million shares (at most) of this company change hands.
That's why I cannot reveal the specific nature of this company's business. And that's why we can only share this information with our smallest, most elite group of subscribers -- the members of our Diligence conference call service.
We believe the share price of this company is going to skyrocket -- and we want to make sure our paid subscribers have the best chance to take advantage of the situation. Eventually, we may be able to write about this company in our regular newsletters. By then, however, the price will likely have multiplied 10, 20, even 50 times.
If you're able to get in early -- long before the crowd -- you have a chance to make some serious money. Based on Dave Lashmet's research on this company and its technology, we believe this stock could realistically return 800% within a year.
Let me show you why...
INVESTMENT CONSIDERATIONS
Today the company is generating no revenue. It pays no dividends. It doesn't even have a price-to-earnings ratio. It holds few hard assets.
Why would you want to invest in such a company?
Because its technology could change the lives of literally billions of people, all over the world...
That's why Dave Lashmet has been following this situation for years. He's met the scientists behind it in person. He's visited the company headquarters and research facility in downtown Boston several times. He's seen the research first hand at one of the most important technology conferences in the world.
As you may know, Dave Lashmet is the Editor and lead researcher for Diligence, our speculative small cap research and conference call service.
This emerging technology company is exactly the kind of opportunity we look for. In fact, this is probably the best opportunity we've ever found.
Obviously, you can't make a decision about a speculative investment like this without a lot of education and due diligence. And that's how Diligence can help you.
The small, early-stage companies in the Diligence portfolio, like the one I've referred to here, are behind tomorrow's "big ideas" -- revolutionary developments that can change the way you live, the way we communicate, and the quality of your life -- and give early investors the chance to make 300%, 500%, even 1,000% or more.
For example:
** A recent Diligence recommendation started Phase III trials for its new anti-flu vaccine this summer, while Phase II trials start this fall for a second vaccine that could prevent strept throat. This recommendation is up 112% in the two years it has been in the portfolio.
** Another Diligence company controls the critical technology for a new kind of portable power for cell phones. Its billion-dollar secret? A liquid that frees hydrogen from methanol. We believe this company -- up 91% since it was recommended -- will lead a fundamental shift away from battery power.
** And our current recommendation -- up 106% since we added it to the portfolio in March 2003 -- has 77 issued US patents on a new retinal display technology that safely produces true 3-D images.
We believe these companies, and the rest of the companies in the Diligence portfolio, have a lot further to go.
It's a fact that small-cap stocks beat big "blue chip" stocks (like IBM, Exxon, and General Electric) over the short and long term. Independent research firm Ibbotson Associates found that small-caps have beaten big stocks by 218% since 1926. In fact, 94 of the 100 best-performing stocks of the last year were small-caps, with a market value of less than $250 million.
If you're looking for gains like these, the best way to find them is in small stocks like the one I've been telling you about.
Look at just a few of the tiny companies that have created incredible fortunes in the past 365 days alone:
** Interpharm Holdings, a pharmaceutical company that makes prescription anti-inflammatories, turned a $500 investment into $8,425 -- thanks to 1,585% gains in the last year
** A $750 initial investment in the international telecom firm NTL Inc. would have made you $10,305 just one year later
** 1,184% gains on FARO Technologies, a company that makes portable 3-D measurement systems -- a year after a $1,000 investment, you would have $12,840 today
** Ivanhoe Energy, a company that produces clean fuel from natural gas using gas-to-liquid (GTL) technology, turned a $1,500 original investment into $16,545 in just a year...
Based on our research and the experts we've spoken with, we believe there is another such opportunity today -- in the small Boston company that's involved in an industry named by MIT as "one of 10 emerging developments that will change the world."
If you find investment opportunities like this exciting, I would strongly recommend joining the call next Sunday evening.
Because Diligence only covers small, early-stage companies, I have to warn you that investing in these types of companies comes with inherent risks.
If you are uncomfortable with high-risk investments -- where the chance for total loss of your original investment exists -- Diligence is not for you.
However, if you're the kind of investor who enjoys seeking high-risk, high return investments with a small part of your total investment portfolio, Dave Lashmet and Diligence founder Porter Stansberry do the kind of due diligence and research that you will simply never receive from your broker...
Dave has spent his entire career, in fact, doing just this kind of legwork and research. Before he started Diligence along with Porter, he spent 10 years teaching and writing about medicine and technology at five major research universities -- Miami, Berkeley, Florida, Regensburg, and Minnesota -- and he's currently a doctoral candidate in Cultural Studies of Medicine.
And over the past four years, Dave and Porter have visited more than 50 businesses around the world. They've done follow-up research at Harvard Medical School, Johns Hopkins, MIT, and the Canadian Centers for Disease Control, to name a few. And they attend the most important medical and technology conferences, like the American Association for Cancer Research (in New Orleans and San Francisco), George Gilder's StoreWidth, the Telecosm conference, and the most exclusive telecommunications conference in the industry (it's so exclusive, in fact, that I can't reveal the name of this conference) -- it's held on Cape Cod each year, where 50 of the most important and powerful people in the Internet industry gather to compare notes.
My point is, this kind of research and legwork, while certainly time-consuming and expensive, has yielded great profits for the Diligence portfolio -- the top 10 portfolio recommendations are up a combined 60%.
Never before in the history of the Diligence group has there been a stock with so much potential upside. Typically, we're looking for opportunities that can go 10 for 1 -- big winners.
But, according to Dave, this opportunity simply dwarfs what our research normally turns up. This one is still trading for just over one dollar -- this stock isn't merely "undiscovered," it's totally unknown. But, with Dave's connections in this industry, he was able to find it. No one else -- nobody on Wall Street and no big institutional investors -- know about this one yet.
Think about this: mutual funds typically won't by a stock until it's trading for at least $10. By the time this one hits that price, we'll have already made more than 700% -- more than eight times our original investment. And, as the institutions clamor to get in, the price should shoot much, much higher.
That's why I can't afford to reveal anything more about it in this e-mail. I'm sure you understand.
But you can find out everything you need to know about whether or not this emerging technology company is one you'd invest in by joining us on the next Diligence conference call.
Let me explain.
We'll be revealing the name of this company -- as well as everything we've learned about the prospects of this company's technology -- on November 23, 2003 at 7:30pm, to the subscribers of our Diligence group.
Joining Dave Lashmet on next Sunday's Diligence conference call will be the CEO and the Vice President of this company. And to help us vet the opportunity, and understand this company's technology, we've invited an outside expert to join us -- he's a top professor at Harvard and one of the most experienced people in the world at assessing this kind of technology.
After you listen to the call and get all the facts, you can make up your own mind and determine whether or not this investment opportunity is right -- and appropriate -- for you.
Diligence -- like all of our services -- only offers independent research. Diligence brings you the best ideas, the best people and the best investments -- so you can make the best decision on whether or not this opportunity is one you would invest in.
If you can't listen in on next Sunday's evening's call for some reason -- but you'd still like to learn about the company we'll be hearing about -- don't worry.
For one week after the call, you can dial a confidential toll-free number to hear the call in its entirety. We'll send you the number as soon as you sign up. So if something comes up and you can't listen in on Sunday night -- no problem. You can listen to it on your own time.
Also, a few days after the call, we post a transcript of the whole thing on our website. You'll be able to get our executive summary and read our research on this company from wherever you are, any time of day, when it's convenient for you.
And as I mentioned, you can check it out before you make a final decision.
Join Diligence today, and if this next conference call doesn't meet all of your expectations, simply cancel your subscription. We'll refund the complete value of the unused portion of your subscription.
As you would imagine, with our success, demand for a "seat" in Diligence has grown considerably. Thus, we're currently only offering access to our Diligence group at the full $5,000 price. For that, you'll receive the next call and a year's worth of monthly conference calls and research, plus access to our past recommendations on the Diligence subscriber-only website.
Or, instead of paying upfront, you can choose to "pay as you go," in monthly installments. This option costs $458 per month. Obviously, you'll get a better deal by paying for the whole year up-front. And you can always cancel at any time.
To sign up online, click the "Subscribe Now" button below.
By the way, if you're able to sign up online, we will give you a 10% discount. And, you'll receive a confirmation e-mail right away. This e-mail will give you access to the Diligence website... plus the details on the November 23 call, including the number to call.
Alternately, if you have any questions about Diligence, or you simply prefer to do business over the phone, you may call our VIP customer service office toll-free: 1-866-411-7859. We've recently added two new employees to better serve our top customers.
I would urge you to join us now. This opportunity won't last more than a few months. And, in a situation like this, it can really pay off to be in early. |
